- Poster presentation
- Open access
- Published:
Clinical utility of using C-reactive protein and procalcitonin as biomarkers for a novel neonatal sepsis diagnostic platform (ASCMicroPlat)
Critical Care volume 16, Article number: P106 (2012)
Background
Neonatal sepsis contributes significantly to morbidity and mortality and encompasses a multisystemic inflammatory response to a microorganism. A lack of suitable diagnostic biomarkers and delays in microbe identification (48 to 72 hours) challenge clinical decision-making. C-reactive protein (CRP) is the current biomarker for sepsis in patients; however, use of earlier markers such as procalcitonin (PCT) could prove more effective. This study aims to assess the clinical utility of combining CRP and PCT for a novel sepsis diagnostic biomarker platform (ASCMicroPlat).
Methods
Blood samples were obtained from 350 infants evaluated for sepsis at the Coombe Women and Infants University Hospital. Eligible infants met one or more inclusion criteria: age ≤6 weeks, clinical sepsis signs, and/or maternal sepsis risk factors. The puncture site was sterilized with alcohol prior to phlebotomy for microbial and biomarker tests. Blood was collected in clotting activator tubes, and incubated at room temperature for 1 hour before centrifuging to separate out serum for later acute-phase protein quantification. For gold-standard tests, an immunoturbimetric CRP assay was performed using a Beckman analyser and a chemiluminescent Elecsys BRAHMS PCT immunoassay using a Cobas e602 analyser.
Results
The mean age of infant evaluation was 2.29 ± 10.37 days. The average gestational age at birth was 37.04 weeks (4.27), 30% of which were preterm. Eighteen out of 350 samples (5%) were blood culture positive. Thirteen samples met the criteria for a laboratory-confirmed bloodstream infection (LCBSI), the most common organisms being Escherichia coli (28%) and Streptococcus agalactiae (22%). CRP results (n = 350) ranged from ≤0.1 to 226 mg/l, sepsis-positive (≥5 mg/l) CRP tests occurred in 69% of LCBSI. PCT quantified samples to date (n = 100) ranged from 0.03 to 67.23 ng/ml. Both analytes featured in higher cases that suggested sepsis than positive blood culture numbers: 56 out of 350 cases had CRP levels ≥5 mg/l, for PCT 23 out of 100 individuals tested positive at the cutoff (>0.5 ng/ml) for bacterial infection.
Conclusion
Sepsis diagnosis requires accurate detection biomarkers; preliminary study findings show that CRP is present in the majority of bloodstream infections. Furthermore, results using both biomarkers suggest that blood culture results do not indicate all cases of true sepsis. Further research will correlate the completed CRP and PCT gold-standard dataset with that produced by ASCMicroPlat PCR-based assays to assess the clinical utility of this device for sepsis diagnostics.
Author information
Authors and Affiliations
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
McAllister, K., Sheridan-Pereira, M., O'Sullivan, N. et al. Clinical utility of using C-reactive protein and procalcitonin as biomarkers for a novel neonatal sepsis diagnostic platform (ASCMicroPlat). Crit Care 16 (Suppl 3), P106 (2012). https://doi.org/10.1186/cc11793
Published:
DOI: https://doi.org/10.1186/cc11793